Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24985158 | 1.00 | CFTR (0.33) | CFTRARRORCPOLB | |
| SCHEMBL24986395 | 0.96 | AR (0.32) | ARPOLB | |
| SCHEMBL24986394 | 0.96 | AR (0.32) | ARPOLB | |
| SCHEMBL24984848 | 0.95 | AR (0.32) | ARPOLB | |
| SCHEMBL24984845 | 0.95 | AR (0.32) | ARPOLB | |
| SCHEMBL24984849 | 0.95 | AR (0.32) | AR | |
| SCHEMBL24984850 | 0.95 | AR (0.32) | AR | |
| SCHEMBL24986197 | 0.95 | AR (0.31) | AR | |
| SCHEMBL24986192 | 0.95 | AR (0.31) | AR | |
| SCHEMBL23905274 | 0.94 | AR (0.33) | ARPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572367-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | CFTR 283/4885AR 4719/4885RORC 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.